abstract_id,endpoint_name,endpoint_decision_rule,endpoint_type,endpoint_id
2271,changes in immune cell infiltration and other biomarkers related to treatment response,Superiority of post-treatment vs. pre-treatment clonal expansion of tumor-infiltrating CD8+ T cells.,exploratory,119
1089,unexpected adverse events (AE),Absence of unexpected adverse events.,not_stated,62
4718,Tolerability / Recommended Dose Selection,Determine the recommended dose for Part Ib based on safety and tolerability in the dose escalation phase (3+3 design).,primary,239
1615,central-assessed confirmed objective response rate (ORR) according to RECIST v1.1,A Bayesian approach was used to evaluate eligible patients in the main cohort... Expected ORR was set at 40% and a threshold at 10%.,primary,95
42,pathological complete response (pCR) rate in the breast and axilla (ypT0/is ypN0),prespecified non-inferiority margin of -10%,primary,326
2242,Association between elevated tissue HER2 CNV and tumor shrinkage,p < 0.05 for statistical significance,exploratory,115
2242,Change in plasma HER2 gain detection rate from T0 to T1,p < 0.05 for statistical significance,exploratory,116
4389,major pathological response (MPR),p < alpha for superiority,primary,228
4389,event-free survival (EFS),p-value ≤0.002 required for statistical significance at interim analysis,secondary,227
4069,incidence of dose-limiting toxicities (DLTs; Phase 1A),The occurrence of dose-limiting toxicities (DLTs) during Phase 1A.,primary,215
4396,Progression-Free Survival (PFS) rate at 6 months,PFS rate at 6 months of 40%,primary,231
1850,safety which measures are incidence and severity of adverse events within 28 days,Absence of severe adverse events.,primary,106
3898,response rate,target of at least 1 response in 12 patients,primary,294
3364,overall survival (OS),Superiority of nimotuzumab + chemotherapy over chemotherapy alone on Overall Survival.,primary,166
3364,progression-free survival (PFS),Superiority of nimotuzumab + chemotherapy over chemotherapy alone on Progression-Free Survival.,secondary,167
3364,Adverse Events,No significant difference in adverse events between the two groups.,not_stated,165
5203,Maximum tolerated dosage(s) (MTD),Determine the maximum tolerated dosage(s) (MTD).,primary,7
5203,Recommended phase 2 dosage(s) (RP2D),Determine the recommended phase 2 dosage(s) (RP2D).,primary,8
3390,objective response rate (ORR) at 2 weeks after the completion of induction therapy,Observed ORR > 80% (null hypothesis),primary,171
5097,objective response rate (ORR) by RECIST 1.1,"H0=23%, Ha=48%",primary,254
5097,safety by CTCAE v5.0 and adverse events (AEs) of special interest (AESIs),The primary endpoint of the triplet was safety by CTCAE v5.0 and adverse events (AEs) of special interest (AESIs).,primary,255
1346,Best RECIST Response,Inferred superiority test with alpha=0.05.,not_stated,84
1346,Progression-free survival (PFS),Inferred superiority test with alpha=0.05.,not_stated,88
1346,Overall survival (OS),Inferred superiority test with alpha=0.05.,not_stated,87
1346,Grade ≥3 CNS treatment-related toxicity,Inferred safety test for no significant difference with alpha=0.05.,not_stated,86
1346,Grade 5 treatment-related toxicity,Inferred safety test for no significant difference with alpha=0.05.,not_stated,85
4082,recommended phase 2 dose (RP2D),Determine the recommended phase 2 dose (RP2D).,primary,216
1884,Overall survival (OS),Demonstrate a statistically significant improvement in Overall Survival (OS) for the experimental arm compared to the control arm.,primary,103
1884,PFS,Demonstrate a statistically significant improvement in Progression-Free Survival (PFS) for the experimental arm compared to the control arm.,not_stated,104
1884,ORR,Demonstrate a statistically significant improvement in Objective Response Rate (ORR) for the experimental arm compared to the control arm.,not_stated,102
1884,disease control rate,Demonstrate a statistically significant improvement in disease control rate for the experimental arm compared to the control arm.,not_stated,105
49,invasive disease-free survival (IDFS),p < 0.049 for statistical significance,primary,342
49,DRFI,Superiority (p < alpha or CI for HR excludes 1.0),secondary,340
49,OS,Superiority (p < alpha or CI for HR excludes 1.0),secondary,341
3938,Dose-Limiting Toxicity (DLT),target toxicity probability .30,primary,214
3938,Association of MRD+ disease with OS,The 95% credible interval for the hazard ratio must exclude 1 to be considered significant.,exploratory,212
3938,Association of age > 60 with OS,The 95% credible interval for the hazard ratio must exclude 1 to be considered significant.,exploratory,213
3749,RP2D for the combination,Determine the Recommended Phase 2 Dose (RP2D) based on the observation of Dose Limiting Toxicities (DLTs).,primary,193
3626,progression-free survival (PFS),"Ho: Median=12 mo vs Ha: 21 mo or a 75% improvement, power of 80% with one-sided alpha 0.2, n=57, 37 PFS events required",primary,175
3626,overall survival (OS),Superiority test with p < 0.05,secondary,174
1946,pCR rate,the experimental regimen would have been considered promising if at least 21 pCRs were observed out of 63 enrolled pts,primary,108
2508,any grade of thrombocytopenia during the radiotherapy and 1 month after the radiotherapy,Incidence of thrombocytopenia ≤ 15%,primary,279
6250,Safety profiles,No significant differences in the occurrence or severity of TRAEs.,secondary,52
2898,patient-reported quality-of-life,Show a statistically significant improvement from baseline.,secondary,138
1727,maximum tolerated dose (MTD),Determine MTD based on dose-limiting toxicities (DLTs) using an accelerated titration design.,primary,269
4318,double negativity rate (PET/CT FDG 5PS score ≤3 + MRD−),Statistical significance is determined by p < 0.05 or a 95% CI for the odds ratio that excludes 1.,not_stated,226
4318,double negativity + ≥CR,Statistical significance is determined by p < 0.05 or a 95% CI for the odds ratio that excludes 1.,not_stated,225
4318,PFS in pts with plasmacytoma at BL,Statistical significance is determined by p < 0.05 or a 95% CI for the hazard ratio that excludes 1.,not_stated,224
4318,"PET/CT 5PS score ≤3 and MRD−, % in patients with plasmacytoma",Statistical significance is determined by p < 0.05 or a 95% CI for the odds ratio that excludes 1.,not_stated,223
4318,"PET/CT 5PS score ≤3 and MRD− + ≥CR, % in patients with plasmacytoma",Statistical significance is determined by p < 0.05 or a 95% CI for the odds ratio that excludes 1.,not_stated,222
3078,proportion of pts with undetectable PSA (PSA<0.1) at 12 months from treatment start in pts with recovered testosterone (T),pre-specified threshold for activity for the B2 expansion of 4 pts,primary,149
4854,Objective response rates (ORR),p < 0.05 for statistical significance,not_stated,299
4854,6-month duration of response (DOR) rate,p < 0.05 for statistical significance and HR CI not crossing 1.0,not_stated,297
4854,6-month progression free survival (PFS) rate,p < 0.05 for statistical significance and HR CI not crossing 1.0,not_stated,298
4854,grade 3 or higher immune-related adverse reactions,No significant increase in harm,not_stated,300
2937,12m-RFS rate by molecular subtype,p < 0.05 for statistical significance,exploratory,139
2937,Association of TOP1 gene expression with 12m-RFS rate,p < 0.05 for statistical significance,exploratory,140
2937,Association of Trop-2 gene expression with ypT response,p < 0.05 for statistical significance,exploratory,141
5240,maximum tolerated dose (MTD),The study implemented the Bayesian Optimal Interval (BOIN) design.,primary,9
4633,safety,The safety profile is consistent with known toxicities and no new safety findings are observed.,primary,238
1147,objective response rate (ORR),Threshold response rate of 5% with a one-sided significance level of 5% and a power of 80%.,primary,64
9,disease-free survival (DFS),The stratified log-rank p-value must cross the pre-specified efficacy boundary of 0.009.,primary,308
34,3-year disease-free survival,Superiority based on Hazard Ratio (HR) < 1 and p-value < 0.05.,primary,312
34,overall survival,Superiority based on Hazard Ratio (HR) < 1 and p-value < 0.05.,not_stated,313
34,serious adverse event,No significant increase in serious adverse events compared to placebo.,not_stated,314
3637,Event-Free Survival (EFS),Superiority is met if the upper bound of the 95% CI for the Hazard Ratio (HR) is < 1.,primary,182
3637,Overall Survival (OS),Superiority is met if the upper bound of the 95% CI for the Hazard Ratio (HR) is < 1.,key secondary,185
3637,Locoregional Control (LRC),Superiority is met if the upper bound of the 95% CI for the Hazard Ratio (HR) is < 1.,exploratory,183
3637,Distant Metastasis-Free Survival (DMFS),Superiority is met if the upper bound of the 95% CI for the Hazard Ratio (HR) is < 1.,exploratory,180
3637,EFS in pts with PD-L1 CPS ≥1,Superiority is met if the upper bound of the 95% CI for the Hazard Ratio (HR) is < 1.,exploratory,181
3637,OS in pts with PD-L1 CPS ≥1,Superiority is met if the upper bound of the 95% CI for the Hazard Ratio (HR) is < 1.,exploratory,184
2998,Safety,Evaluate the safety of intravesical BH011.,not_stated,144
2998,Clinical efficacy independence from pathology and BCG failure type,P > 0.05 to demonstrate independence between subgroups.,exploratory,143
5200,event-free status at 4-months,"at Stage 2, ≥11 of 34 patients 4-months event-free for evidence of efficacy.",primary,4
4416,disease-free survival (DFS),Superiority is met if p < 0.05 and the hazard ratio confidence interval excludes 1.,primary,232
4416,overall survival (OS),Superiority is met if p < 0.05 and the hazard ratio confidence interval excludes 1.,secondary,233
4416,toxicity,Safety is met if no new or unacceptable safety signals are observed.,secondary,234
6060,safety and tolerability of abema / maximum tolerated dose (MTD),Identify a maximum tolerated dose (MTD) using a 3+3 dose de-escalation design.,primary,29
2468,mPFS in CPS <1 vs CPS ≥1 subgroups,Statistical significance is determined by p < 0.05.,exploratory,277
2468,mOS in CPS <1 vs CPS ≥1 subgroups,Statistical significance is determined by p < 0.05.,exploratory,275
2468,mPFS in subgroups with first-line mPFS ≥6 and <6 months,Statistical significance is determined by p < 0.05.,exploratory,278
2468,mOS in subgroups with first-line mPFS ≥6 and <6 months,Statistical significance is determined by p < 0.05.,exploratory,276
2502,MPR in patients with diffuse classification vs intestinal and mixed,p < 0.05 for superiority,exploratory,280
23,PSA Progression Free Survival (PSA-PFS),The upper bound of the 95% CI for the Hazard Ratio must be less than the non-inferiority margin of 1.37.,primary,336
23,PSA response rates [PSA30],p < 0.05 for statistical significance,secondary,337
23,PSA response rates [PSA50],p < 0.05 for statistical significance,secondary,338
23,overall survival (OS),p < 0.05 for statistical significance and CI for HR excludes 1,secondary,339
23,Grade >3 toxicities,p < 0.05 for statistical significance of difference,not_stated,335
1205,ORR by CD47 non-specific cell proportion,p < 0.05 for statistical significance,exploratory,69
1205,DCR by CD47 non-specific cell proportion,p < 0.05 for statistical significance,exploratory,68
29,overall survival (OS),The criteria for early reporting were a fixed sample p-value from a stratified log-rank test ≥ 0.3156 for futility and ≤ 0.0054 for efficacy.,primary,347
2254,mPFS in patients with baseline tissue CDK4/6 pathway alterations vs without,p < 0.05 for statistical significance,exploratory,118
2254,mOS in patients with baseline tissue CDK4/6 pathway alterations vs without,p < 0.05 for statistical significance,exploratory,117
4492,objective response rate (ORR),"If more than 4 out of the first 18 pts achieved a response, the cohort would expand to include 33 pts.",primary,235
